摘要
癌症已经是全球范围内的一个主要健康问题,因此基于当前研究成果更加有效地治疗策略不断地被提出。慢性的、无法检测的炎症被广泛地认为能够引发癌症。先天性的免疫系统作为第一道防线,其中炎症体是必需的以维持炎性因子和抗炎因子间的微妙平衡,以保证产生一个合适的免疫反应且不伤害到宿主。研究已经揭示出一个显著的,但是矛盾的宿主免疫反应和肿瘤发生间的联系。确实,由危险信号激活的多个蛋白复合免疫炎症体在癌症发生和发展过程中似乎起着多种和有时是矛盾的、抑制的或者刺激的作用,并伴有一个显著的环境依赖性。多效性的炎症体可能作用于细胞自治水平并通过炎症突触类型的程序性细胞凋亡来消除恶性细胞,但是相反的,也有可能产生有利于肿瘤细胞生长和它们的微环境营养的因子。此外,依靠天冬氨酸-1激活的炎性体能够引发无菌炎症,并且提供致癌因素,所有抗原提呈细胞能够引出抗肿瘤免疫反应。明确的说,环境特异影响肿瘤发生的炎症体代表了一个新的研究领域,具有潜在作用以进出一个有前景的新颖的靶标用于癌症治疗。
关键词: 癌症,天冬氨酸-1,炎症,炎症体,促炎性细胞因子,细胞死亡。
Current Drug Targets
Title:Inflammasome, Inflammation and Cancer: An Interrelated Pathobiological Triad
Volume: 16 Issue: 3
Author(s): Gyorgyi Muzes and Ferenc Sipos
Affiliation:
关键词: 癌症,天冬氨酸-1,炎症,炎症体,促炎性细胞因子,细胞死亡。
摘要: Cancer represents a major health problem worldwide, therefore on the basis of current research results constantly more effective therapeutic strategies are expected. Chronic, unchecked inflammation has widely been suggested to trigger carcinogenesis. The innate immune system ensures a first line host defense in which the inflammasome is essential maintaining a delicate balance betweeen pro- and anti-inflammatory signals in order to generate an appropriate immune response without harming the host. Studies have revealed a remarkable, but contradictory link of host inflammatory responses to tumorigenesis. Indeed, activation of the multiprotein complex inflammasome by danger signals seems to play diverse and sometimes conflicting, suppressive or stimulatory role in cancer development and progression with a significant context-dependency. The pleitropic inflammasomes may act at cellautonomous level to eliminate malignant cells via the programmed cell death type of inflammatory pyroptosis, but on the contrary, may favor the production of gowth and trophic factors for tumor cells and their microenvironment. Further, upon caspase-1 activation the inflammasome can provoke sterile inflammation, and thus facilitate carcinogenesis, though in antigen-presenting cells it can elicit anti-tumor immune responses. Clarifying the exact, context-specific impact of inflammasomes on tumorigenesis represents a new research area with the potential to introduce promising novel targets for cancer therapeutics.
Export Options
About this article
Cite this article as:
Gyorgyi Muzes and Ferenc Sipos , Inflammasome, Inflammation and Cancer: An Interrelated Pathobiological Triad, Current Drug Targets 2015; 16 (3) . https://dx.doi.org/10.2174/1389450115666141229154157
DOI https://dx.doi.org/10.2174/1389450115666141229154157 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins
Current Molecular Medicine Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design Cytokine-Induced Inflammatory Liver Injuries
Current Molecular Medicine Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
Anti-Cancer Agents in Medicinal Chemistry Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Current Pharmaceutical Design Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery A Microextraction Liquid-Chromatographic Determination of Aristolochic Acid I in Urine, Flour, and Aristolochiaceae Fruit
Current Pharmaceutical Analysis Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry p53 Regulation of Energy Metabolism and Mitochondria Regulation of p53 in Cancer Cells: An Insight into the Role of Manganese Superoxide Dismutase
Current Pharmaceutical Biotechnology Reactive Oxygen Species, Inflammation, and Lung Diseases
Current Pharmaceutical Design Insights in microRNAs Biology
Current Topics in Medicinal Chemistry Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience
Reviews on Recent Clinical Trials Phytosterols in Cancer: From Molecular Mechanisms to Preventive and Therapeutic Potentials
Current Medicinal Chemistry Multidrug Resistance in Cancer Chemotherapy and Xenobiotic Protection Mediated by the Half ATP-Binding Cassette Transporter ABCG2
Current Medicinal Chemistry - Anti-Cancer Agents Nuclear Medicine: from Photons to Physiology
Current Pharmaceutical Design